Phase dyssynchrony and 123I-meta-iodobenzylguanidine innervation imaging towards standardization

123I-Meta-iodobenzylguanidine Sympathetic Imaging: Standardization and Application to Neurological Diseases

(123)I-meta-iodobenzylguanidine (MIBG) has become widely applied in Japan since its introduction to clinical cardiology and neurology practice in the 1990s. Neurological studies found decreased cardiac uptake of (123)I-MIBG in Lewy-body diseases including Parkinson's disease and dementia with Lewy bodies. Thus, cardiac MIBG uptake is now considered a biomarker of Lewy body diseases. Although sc...

Standardization of 123I-meta-iodobenzylguanidine myocardial sympathetic activity imaging: phantom calibration and clinical applications

PURPOSE Myocardial sympathetic imaging with 123I-meta-iodobenzylguanidine (123I-mIBG) has gained clinical momentum. Although the need for standardization of 123I-mIBG myocardial uptake has been recognized, the availability of practical clinical standardization approaches is limited. The need for standardization includes the heart-to-mediastinum ratio (HMR) and washout rate with planar imaging, ...

Three-dimensional 123I-meta-iodobenzylguanidine cardiac innervation maps to assess substrate and successful ablation sites for ventricular tachycardia: feasibility study for a novel paradigm of innervation imaging.

BACKGROUND Innervation is a critical component of arrhythmogenesis and may present an important trigger/substrate modifier not used in current ventricular tachycardia (VT) ablation strategies. METHODS AND RESULTS Fifteen patients referred for ischemic VT ablation underwent preprocedural cardiac (123)I- meta-iodobenzylguanidine ((123)I-mIBG) imaging, which was used to create 3-dimensional (3D)...

Meta-Iodobenzylguanidine Imaging: From Standardization to Mortality Risk Models in Heart Failure

123 I-meta-iodobenzylguanidine (MIBG) is a potent prognostic marker of chronic heart failure (CHF). However, inter-institutional variations due to methodological variations required minimization before 123 I-MIBG findings could be universally applied to the diagnosis, treatment and prognosis of CHF. Therefore, protocols including data acquisition, setting regions of interest for calculating hea...

123I-meta-iodobenzylguanidine in patients with chronic heart failure: technical aspects, conceptual issues, and future prospects.